<DOC>
	<DOCNO>NCT01142414</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , cisplatin fluorouracil , work different way stop growth tumor cell , either kill cell stop divide . Radiation therapy use high-energy x-ray kill tumor cell . Specialized radiation therapy delivers high dose radiation directly tumor may kill tumor cell cause less damage normal tissue . Monoclonal antibody , panitumumab , block tumor growth different way . Some block ability tumor cell grow spread . Others find tumor cell help kill carry tumor-killing substance . It yet know whether chemotherapy give together radiation therapy effective without panitumumab treat patient advanced cancer hypopharynx , oropharynx , larynx , oral cavity . PURPOSE : This randomized phase III trial study chemotherapy give together radiation therapy see well work compare chemotherapy radiation therapy give together panitumumab treat patient undergone surgery advance hypopharyngeal cancer , oropharyngeal cancer , laryngeal cancer , oral cavity cancer high risk recurrence .</brief_summary>
	<brief_title>Chemotherapy Radiation Therapy With Without Panitumumab Treating Patients Who Have Undergone Surgery Advanced Hypopharyngeal Cancer , Oropharyngeal Cancer , Laryngeal Cancer , Oral Cavity Cancer High Risk Recurrence</brief_title>
	<detailed_description>OBJECTIVES : Primary - To determine addition concurrently administer panitumumab standard adjuvant chemoradiation , 1 2 cisplatin-based regimen , significantly prolong disease-free survival patient macroscopically completely resect , advance squamous cell carcinoma hypopharynx , oropharynx , larynx , oral cavity high risk recurrence . Secondary - To determine pre-surgery dose panitumumab alter RNA expression several gene change provide additional prognostic information use future patient management . ( Exploratory ) - Measure difference RNA expression RNA microarray result analyze create gene expression classifier check outcome prediction association disease free survival regulation glucose metabolism measure FDG-PET . ( Exploratory ) - To create European biobank biological sample use future research project disease . ( Exploratory ) - To predict radiation-induced normal tissue toxicity base vitro lymphocyte apoptosis test SNPs analysis . ( Exploratory ) - To assess impact radiation-induced side effect ( swallow dysfunction xerostomia ) patient 's quality life . OUTLINE : This multicenter study . Patients stratify treatment center , radiotherapy technique ( 3D-CRT v IMRT ) , chemotherapy regimen ( European Organization Research Treatment Cancer [ EORTC ] ) v Arbeitsgemeinschaft Radiology Oncology [ ARO ] schedule ) , tumor location ( larynx v oropharynx v hypopharynx vs oral cavity ) , pN-stage ( pN0-2 v pN3 ) , pT-stage ( pT1-2 v pT3-4 ) , margin/extracapsular extension ( ECE ) status ( ECE+ margin &lt; 5 mm vs ECE- margin &lt; 5 mm v ECE+ margin &gt; 5 mm ) , biological pre-study participation ( yes v ) , p16 status ( positive v negative v indeterminable ) . Patients randomize 1 2 treatment arm . - Arm I ( chemoradiotherapy ) : Within 4-8 week surgery , patient undergo 3D-conformal intensity-modulated radiotherapy daily 5 day week week 1-7 . Patients also receive concurrent chemotherapy comprise either cisplatin IV 1-2 hour day 1 , 22 , 43 ( EORTC schedule ) OR cisplatin IV 1-2 hour fluorouracil IV 24 hour day 1-5 29-33 ( ARO schedule ) , absence disease progression unacceptable toxicity . - Arm II ( chemoradiotherapy plus panitumumab ) : Within 4-8 week surgery , patient undergo 3D-conformal intensity-modulated radiotherapy receive concurrent chemotherapy ( EORTC schedule ARO schedule ) arm I . Patients also receive panitumumab IV 1 hour day 1 , 8 , 15 , 22 , 29 , 36 , 43 . Blood sample collect periodically biomarker correlative study translational research . Patients complete quality-of-life EORTC questionnaires QLQ-C30 , QLQ-HN35 , PSS-HN periodically . After completion study treatment , patient follow every 3 month 2 year every 6 month 3 year .</detailed_description>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Recurrence</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm primary squamous cell carcinoma hypopharynx , oropharynx , larynx , oral cavity Stage pT12 pN+ pT34 pN ( stage IIIIVB ) disease No distant metastases No recurrent disease Resectable disease Has undergone surgical resection carcinoma p16 immunohistochemistry assay perform tissue section take surgical procedure No laser surgery Potentially highrisk locoregional recurrence , define fulfil ≥ 1 follow criterion : Close surgical margin ( i.e. , margin 1 mm &lt; 5 mm ) R1resection ( &lt; 1 mm ) ( R2 resection consider eligible ) Extracapsular nodal extension No nasopharynx , nasal cavity , paranasal sinus carcinomas PATIENT CHARACTERISTICS : WHO ECOG performance status 01 Absolute neutrophil ≥ 1.5 x 10^9/L Platelet count ≥ 100 x 10^9/L Hemoglobin ≥ 10.0 g/dL Bilirubin &lt; 1.5 time upper limit normal ( ULN ) AST &lt; 3 time ULN Alkaline phosphatase &lt; 3 time ULN Calculated creatinine clearance ≥ 60 mL/min Calcium ≤ 11.5 mg/dL 2.9 mmol/L Magnesium ≥ 1.2 mg/dL 0.5 mmol/L Fertile patient must use effective contraception method study 6 month last treatment dose Not pregnant nursing No know allergic hypersensitivity reaction component study treatment No concurrent serious illnesses medical condition , include follow : History evidence interstitial pneumonitis pulmonary fibrosis Unstable cardiac disease despite treatment NYHA class IIIIV congestive heart failure Clinically significant abnormal ECG LVEF institutional low limit normal Known HIV infection condition persistent immunodeficiency Significant neurologic psychiatric disorder Active uncontrolled infection Active disseminate intravascular coagulation Symptomatic peripheral neuropathy ( CTCAE 4.0 `` peripheral sensory neuropathy paresthesia '' ) ≥ grade 2 ototoxicity ( CTCAE 4.0 `` hearing impaired '' ) ≥ grade 2 , unless due trauma mechanical impairment due tumor mass Other serious underlie medical condition could impair ability patient participate study No malignancy within past 5 year basal cell squamous cell carcinoma skin situ carcinoma cervix Patients diseasefree &gt; 5 year allow No know drug abuse No psychological , familial , sociological ( e.g. , severe alcohol addiction expect hamper protocol compliance ) , geographical condition potentially hamper compliance study protocol followup schedule PRIOR CONCURRENT THERAPY : No prior chemotherapy radiotherapy carcinoma head neck No prior radiotherapy head neck region No prior exposure EGFR pathwaytargeting therapy No participation another interventional clinical trial within past 30 day No concurrent granulocyte colonystimulating factor ( GCSF ) erythropoietin No concurrent investigational drug and/or anticancer treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>stage III squamous cell carcinoma hypopharynx</keyword>
	<keyword>stage IV squamous cell carcinoma hypopharynx</keyword>
	<keyword>stage III squamous cell carcinoma larynx</keyword>
	<keyword>stage IV squamous cell carcinoma larynx</keyword>
	<keyword>stage III squamous cell carcinoma lip oral cavity</keyword>
	<keyword>stage IV squamous cell carcinoma lip oral cavity</keyword>
	<keyword>stage III squamous cell carcinoma oropharynx</keyword>
	<keyword>stage IV squamous cell carcinoma oropharynx</keyword>
	<keyword>tongue cancer</keyword>
</DOC>